Browsing Tag
Sotyktu
4 posts
Takeda (NYSE: TAK) boosts psoriasis ambitions as Phase 3 zasocitinib data sharpen oral TYK2 challenge
Takeda’s Phase 3 zasocitinib psoriasis data could reshape the oral TYK2 race. Read what it means for Takeda, rivals, and the market now.
The next frontier: Can CAR T therapy become a one-time cure for autoimmune diseases?
Can CAR T therapy move beyond cancer and offer one-time remission for autoimmune disease? A deep look at early data, industry shifts, and clinical implications.
Can Bristol Myers Squibb’s CD19 NEX-T therapy replace lifelong immunosuppression? Early Phase 1 data raises the question
Bristol Myers Squibb’s new CAR T data suggests immune reset potential in lupus, systemic sclerosis, and inflammatory myopathies. Read how the paradigm may shift.
Sotyktu joins Eliquis in Bristol Myers’ direct-to-patient experiment — Is this the future of pharma distribution?
Bristol Myers Squibb adds Sotyktu to its DTC channel with 86% discount, reshaping drug pricing and patient access. See why this matters for pharma.